Human CYPs involved in drug metabolism: Structures, substrates and binding affinities

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 6, 2010, Pages 661-674

  Lewis, David FV ^a,b   Ito, Yuko ^c  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

CYP; Drug metabolism; Molecular modelling; Quantitative structureactivity relationships; Substrate binding

Indexed keywords

4 NITROANISOLE; AMFEBUTAMONE; CAFFEINE; CHLORAMPHENICOL; CHLORZOXAZONE; COTININE; COUMARIN; CYCLOPHOSPHAMIDE; CYTOCHROME; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIAZEPAM; DICLOFENAC; NICOTINE; NIFEDIPINE; OMEPRAZOLE; PACLITAXEL; PARACETAMOL; RETINOIC ACID; ROSIGLITAZONE; TEGAFUR; UNINDEXED DRUG; ZOPICLONE; CYTOCHROME P450; DRUG;

AUTOMATION; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; LIPOPHILICITY; METABOLIC RATE; MOLECULAR DOCKING; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952492782     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003674380     Document Type: Review

References (43)

1. Isin EM, Guengerich FP. Substrate binding to cytochromes P450. Anal Bioanal Chem 2008;392:1019-30
2. Furge LL, Guengerich FP. Cytochrome P450 enzymes in drug metabolism and chemical toxicology. Biochem Mol Biol Educ 2006;34:66-74
3. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor, Cytochrome P450 Kluwer/Plenum. Chapter 10. New York; 2005. p. 377-530
4. Lewis DFV. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004;5:305-18
5. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83
6. Lewis DFV. Guide to cytochromes P450 structure and function. Taylor & Francis, London; 2001
7. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34:83-448
8. Makris TM, Denisov I, Schlichting I, Sligar SG. Activation of molecular oxygen by cytochrome P450. In: Ortiz de Montellano PR, editor, Cytochrome P450 Kluwer/Plenum. Chapter 5. New York; 2005. p. 149-82
9. Lewis DFV, Pratt JM. The cytochrome P450 catalytic cycle and mechanism of oxygenation. Drug Metab Rev 1998;30:739-86
10. Newcomb M, Le Tadic M-H, Putt DA, Hollenberg PF. An incredibly fast apparent oxygen rebound rate constant for hydrocarbon hydroxylation by cytochrome P450 enzymes. J Am Chem Soc 1995;117:3312-13
11. Newcomb M, Hollenberg PF, Coon MJ. Multiple mechanisms and multiple oxidants in P450-catalyzed hydroxylations. Arch Biochem Biophys 2003;409:72-9
12. Shaik S, De Visser SP. Computational approaches to cytochromes P450 function. In: Ortiz de Montellano PR, editor, Cytochrome P450 Kluwer/Plenum. Chapter 2. New York; 2005. p. 45-85
13. Hansch C, Zhang L. Quantitative structure-activity relationships of cytochrome P450. Drug Metab Rev 1993;25:1-48
14. Hansch C, Mekapati SB, Kurup A, Verma RP. QSAR of cytochrome P450. Drug Metab Rev 2004;36:105-56
15. Gao H, Hansch C. QSAR of P450 oxidation: on the value of comparing kcat and Km with kcat/Km. Drug Metab Rev 1996;28:513-26
16. Ekins S, Bravi G, Binkley S, et al. Three- and four-dimensional quantitative structure-activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 1999;28:994-1002
17. Ekins S, Bravi G, Ring BJ, et al. Three-dimensional quantitative structure-activity relationship analyses of substrates for CYP2B6. J Pharmacol Exp Ther 1999;288:21-9
18. Ekins S, Bravi G, Wikel JH, Wrighton SA. Three-dimensional quantitative structure-activity relationship analyses of substrates for CYP2B6. J Pharmacol Exp Ther 1999;291:424-33
19. Payne VA, Chang Y-T, Loew GH. Homology modeling and substrate binding study of human CYP2C9 enzyme. Proteins Struct Funct Genet 1999;37:176-90
20. Payne VA, Chang Y-T, Loew GH. Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes. Proteins Struct Funct Genet 1999;37:204-17
21. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-62
22. Lewis DFV, Ito Y. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity. Xenobiotica 2009;39:625-35
23. Kleywegt GJ, Jones TA. Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr D 1994;50:178-85
24. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992;44:2089-98
25. Lewis DFV. Human cytochromes P450 associated with the Phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 2003;10:1955-72
26. De Groot MJ, Kirton SB, Sutcliffe MJ. In silico methods for predicting ligand binding determinants of cytochromes P450. Curr Top Med Chem 2004;4:1803-24
27. Cruciani G, Carosati E, De Boeck B, et al. MetaSite: understanding metabolism in human cytochromes P450 from the perspective of the chemist. J Med Chem 2005;48:6970-9
28. Afzelius L, Hasselgren-Arnby C, Carlsson L, et al. State-of-the-art tools for computational site of metabolism predictions: insights and future applications. Drug Metab Rev 2007;39:61-86
29. Kemp CA, Flanagan JU, van Eldik AJ, et al. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. J Med Chem 2004;47:5340-6
30. Terfloth L, Bienfait B, Gasteiger J. Ligand-based models for the isoform specificity of P450 3A4, 2D6 and 2C9 substrates. J Chem Inform Model 2007;47:1688-701
31. Lewis DFV. On the estimation of binding affinity (DGbind) for human P450 substrates based on Km and KD values. Curr Drug Metab 2003;4:331-40
32. Lewis DFV. Hydrogen bonding in human P450-substrate interactions: a major contribution to binding affinity. Sci World 2004;4:1074-80
33. Lewis DFV, Ito Y, Goldfarb PS. Enzyme-substrate binding interaction energies and their application to the cytochrome P450 system. Curr Comput Aided Drug Des 2008;4:111-22
34. Lewis DFV, Ito Y. Cytochrome P450 structure and function: an evolutionary perspective. In: Ioannides C, editor, Cytochromes P45-role in the metabolism and toxicity of drugs and other xenobiotics. Chapter 1. Royal Society of Chemistry, Cambridge; 2008. p. 3-45
35. Lewis DFV, Ito Y. Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. Expert Opin Drug Metab Toxicol 2008;4:1181-6
36. Lewis DFV, Ito Y, Lake BG. Electronic and structural aspects of P450-mediated drug metabolism. Drug Metab Lett 2009;3:87-100
37. Lewis DFV, Jacobs MN, Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 2004;9:530-7
38. Lewis DFV, Lake BG, Dickins M. Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: the importance of compound lipophilicity. J Enzyme Inhib Med Chem 2007;22:1-6
39. Ito Y, Kondo H, Goldfarb PS, Lewis DFV. Analysis of CYP2D6 substrate interactions by computational methods. J Mol Graph Model 2008;26:947-56
40. Levitt M, Perutz MF. Aromatic rings act as hydrogen bond donors. J Mol Biol 1988;201:751-4
41. Lewis DFV, Ito Y, Goldfarb PS. Investigating human P450s involved in rug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily. Curr Drug Metab 2006a;7:589-98
42. Lewis DFV, Ito Y, Goldfarb PS. Structural modeling of the human drug-metabolizing cytochromes P450. Curr Med Chem 2006b; 13:2645-52
43. In: Ioannides C, editor. Cytochromes P450- role in the metabolism and toxicity of drugs and other xenobiotics. Royal Society of Chemistry, Cambridge; 2008